3 news items
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
RVNC
9 May 24
and RHA customer base while also driving deeper account penetration. Overall, we are pleased with the traction we are seeing with DAXXIFY
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
the flexibility to customize treatment intervals for each patient, without being limited by the FDA and payer-defined minimum treatment interval of 12 weeks
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
RVNC
12 Apr 24
or later. These findings suggest that the long-acting symptom control with DAXXIFY® allows physicians the flexibility to customize treatment
- Prev
- 1
- Next